Pentoxifylline in strokes: a clinical study.
The results of a comparative clinical study with pentoxifylline -- a new vasoactive compound -- and xanthinol nicotinate in fifty-eight patients suffering from cerebral thrombosis with hemiplegia or monoplegia, are presented. Pentoxifylline appeared to be more effective in reducing motor deficit and was significantly better in improving the patients' intelligence and memory score. Recovery from speech deficit was equally well seen with both drugs.
D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D005260:Female; D006429:Hemiplegia / Q000188:drug therapy; D006801:Humans; D007360:Intelligence / Q000187:drug effects; D002542:Intracranial Embolism and Thrombosis / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008569:Memory Disorders / Q000188:drug therapy; D010431:Pentoxifylline / Q000627:therapeutic use*; D011674:Pulse / Q000187:drug effects; D011897:Random Allocation; D013064:Speech Disorders / Q000188:drug therapy; D013805:Theobromine / Q000031:analogs & derivatives*; D014971:Xanthinol Niacinate / Q000627:therapeutic use
D014971:Xanthinol Niacinate; D013805:Theobromine; D010431:Pentoxifylline